Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26291377 | 0.87 | GCGR (0.33) | DGAT1SRD5A1CXCR3 | |
| SCHEMBL26291395 | 0.82 | NFKB1 (0.31) | — | |
| SCHEMBL12450286 | 0.81 | ACHE (0.41) | SRD5A1 | |
| SCHEMBL26291402 | 0.79 | NFKB1 (0.34) | SRD5A1USP30AAK1FNTAFNTB | |
| SCHEMBL26291387 | 0.78 | CCR2 (0.40) | DGAT1SRD5A1CCR2USP30BACE1 | |
| SCHEMBL31730506 | 0.78 | SRD5A1 (0.38) | SRD5A1USP30AAK1FNTAFNTB | |
| SCHEMBL23725338 | 0.77 | SRD5A1 (0.33) | SRD5A1USP30 | |
| SCHEMBL30432457 | 0.77 | SRD5A1 (0.33) | SRD5A1USP30 | |
| SCHEMBL22517149 | 0.77 | CETP (0.44) | CCR2 | |
| SCHEMBL31377827 | 0.77 | RIPK1 (0.36) | CCR2CXCR3USP30AAK1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295076-A1 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295076-A1 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295076-A1 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | CYP11B2, ALDH7A1, CYP11B1 | DGAT1 2858/4885SRD5A1 159/4885CCR2 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.